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Pseudomonas aeruginosa is capable of establishing airway infections. Human airway
mucus contains a large amount of lysozyme, which hydrolyzes bacterial cell walls.
P. aeruginosa, however, is known to be resistant to lysozyme. Here, we performed
a genetic screen using a mutant library of PAO1, a prototype P. aeruginosa strain,
and identified two mutants (1bamB and 1fabY ) that exhibited decrease in survival
after lysozyme treatment. The bamB and fabY genes encode an outer membrane
assembly protein and a fatty acid synthesis enzyme, respectively. These two mutants
displayed retarded growth in the airway mucus secretion (AMS). In addition, these
mutants exhibited reduced virulence and compromised survival fitness in two different
in vivo infection models. The mutants also showed susceptibility to several antibiotics.
Especially, 1bamBmutant was very sensitive to vancomycin, ampicillin, and ceftazidime
that target cell wall synthesis. The 1fabY displayed compromised membrane integrity.
In conclusion, this study uncovered a common aspect of two different P. aeruginosa
mutants with pleiotropic phenotypes, and suggests that BamB and FabY could be novel
potential drug targets for the treatment of P. aeruginosa infection.
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INTRODUCTION
Antibiotic-resistant P. aeruginosa strains are emerging at a significantly faster rate than the
introduction of new anti-Pseudomonal agents (Pendleton et al., 2013). Furthermore, prolonged
use of antibiotics has been proven to be a critical risk factor in the selection of multi-drug resistant
variants, especially in the case of P. aeruginosa infection (Merlo et al., 2007). It is, therefore, crucial
to devise a revolutionary strategy to combat P. aeruginosa infection. One such way would be to take
advantage of the host innate defense molecules. Since the early discovery of the inherent lysozyme
resistance of P. aeruginosa (Warren et al., 1955), no significant efforts have been made to increase
the susceptibility of P. aeruginosa to lysozyme.
Lysozyme is an important antibacterial protein that is abundantly present in the human
airway (Duszyk, 2001; Dubin et al., 2004; Dajani et al., 2005). Its enzymatic activity is to
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cleave β-1,4-glycosidic linkages on the N-acetylglucosamine
(NAG) and N-acetylmuramic acid (NAM) polysaccharide chains
within the bacterial peptidoglycan layer (Vanderwinkel et al.,
1995). Lysozyme found in the human airway is more active than
egg-white lysozyme due to distinct structural differences between
the two molecules (Marx et al., 1986). Although lysozyme has
been proposed to play a crucial role in host defense, persistent
P. aeruginosa airway infection is a major cause of morbidity
and mortality in cystic fibrosis (CF) patients. Moreover, higher
lysozyme activity has been detected in the serum and saliva of CF
patients compared with normal individuals (Hughes et al., 1982).
Likewise, lysozyme activity was also higher in bronchoalveolar
lavage fluid (BALF) collected fromCF patients (Sagel et al., 2009).
Together, these results suggest that human lysozyme is ineffective
in killing P. aeruginosa during infection. The lack of lysozyme
effectiveness against P. aeruginosa has also been attributed to its
active production of elastase, a major metalloprotease that can
cleave human lysozyme (Jacquot et al., 1985).
Besides the infection in CF patients, P. aeruginosa is one of
the major pathogens that cause ventilator-associated pneumonia
(VAP). Especially, the pneumonia and sepsis by P. aeruginosa are
the serious threats to the cardiac or thoracic surgical patients and
trauma patients in the Intensive Care Unit (ICU; Berra et al.,
2010). P. aeruginosa can also cause acute lung injury by injecting
the ExoU toxin into the cytosol of eukaryotic cells using Type III
Secretion System (TTSS; Pankhaniya et al., 2004). The acute P.
aeruginosa infection could disrupt the alveolar epithelial barrier
to promote necrosis of lung epithelial cells and sepsis, leading
rapid increase in mortality (Sawa, 2014).
In this study, we aimed to identify novel interventional
approaches that increase the sensitivity of P. aeruginosa to
lysozyme. To this end, we isolated P. aeruginosa mutants
that lost their viability when treated with lysozyme and
sought to describe the genetic and phenotypic bases of their
lysozyme sensitivity. Such defective mutants were found to be
incapable of propagating in airway mucus secretions (AMSs)
or establishing infection in the mouse airway, two locations
where lysozyme is present in high concentrations. Results
provided here will stimulate future works to propose novel




Experiments using human subjects and experimental animals
were performed in strict accordance with guidelines provided
by Yonsei University. Protocols were reviewed and approved
by Institutional Review Board of Yonsei University College of
Medicine. Permit numbers for primary culture of human tissues
and mouse infection experiment were 2014-1842-001 and 2013-
0369-5, respectively.
Bacterial Strains and Growth Conditions
A prototype strain of P. aeruginosa called PAO1 was used in
this study (Yoon et al., 2006). The bacterial strains of the other
species, as listed in Figure 1, were obtained from our laboratory
FIGURE 1 | Intrinsic resistance of P. aeruginosa to lysozyme. Six
different bacterial species were treated with 1 mg/mL lysozyme in 0.5× LB for
16 h. Bacterial cells were enumerated by plating serially-diluted cells on LB
agar plates. Each culture contained an initial inoculum of 1 × 105 cells.
Bacterial cultures were repeated in triplicate, and the mean ± SD values are
displayed. *P < 0.05 vs. CFU of untreated cultures.
stock and were previously reported (Gi et al., 2015). Bacterial
cultures were grown in Luria-Bertani medium (LB; 10 g tryptone,
5 g yeast extract, and 10 g NaCl/l), unless otherwise stated.
Bacterial cells were cultured at 37◦C for 16 h and shaken at
200 rpm. Bacterial growth in AMS and survival following the
treatments with diverse antibiotics were assessed by quantifying
colony forming units (CFUs).
Mutant Library Screen for
Lysozyme-Sensitive Mutants and
Preparation of Airway Mucus Secretion
(AMS)
A transposon (Tn) insertion mutant library of PAO1 was
constructed following the procedures described elsewhere (Lee
et al., 2016). In brief, PAO1 was conjugated with Escherichia coli
SM10/λpir harboring the pBTK30 plasmid (Table 1). Gentamicin
(Gm)-resistant transconjugants were grown on LB agar plates
containing 50 µg/ml Gm and 50 µg/ml Irgasan (Sigma).
Irgasan was added to eliminate E. coli donor cells. To isolate
lysozyme-sensitive mutants, each individual mutant was grown
in 0.5× LB media (50% LB + 50% distilled water) containing
1 mg/mL lysozyme (Sigma) in 96 well plates. Bacterial growth
was monitored by measuring the OD600. The Tn insertion site
of each defective mutant was determined by arbitrary PCR,
followed by DNA sequencing (Lee et al., 2016). Preparation of
AMS samples from Normal Healthy Trachea Epithelial (NHTE)
cells and bacterial growth in AMS were conducted as previously
described (Gi et al., 2015).
Construction of the PA0420, PA3800, and
PA5174 Clean Deletion Mutants
The bioA, bamB, and fabY deletion mutants were created by
allelic replacement as previously described (Lee et al., 2012).
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TABLE 1 | Bacterial strains and plasmids used in this study.
Strains or plasmids Relevant characteristics References or source
P. aeruginosa strains
PAO1 Standard lab strain Yoon et al., 2006
1PA0420 PA01, PA0420 gene deleted This study
1PA3800 PAO1, PA3800 gene deleted This study
1PA5174 PAO1, PA5174 gene deleted This study
1PA3800/pJN105 1PA3800 harboring pJN105 This study
1PA5174/pJN105 1PA5174 harboring pJN105 This study
1PA3800/pJN105::PA3800 1PA3800 harboring pJN105::PA3800 This study
1PA5174/pJN105::PA5174 1PA5174 harboring pJN105::PA5174 This study
E. coli strains
SM10/λpir Kmrthi-1 thr leu tonA lacY supE recA::RP4–2-Tc::Mu pir+, for conjugal transfer Simon et al., 1983
OTHER BACTERIAL SPECIES
Staphylococcus aureus ATCC 29213 Lab collection
Bacillus subtilis ATCC 6633 Lab collection
Escherichia coli ATCC 25922 Lab collection
Salmonella typhimurium LT2 strain Lab collection
Listeria monocytogenes ATCC 19111 Lab collection
PLASMIDS
pBTK30 Transposon vector for construction of a random mutant library, Gmr Kim et al., 2012
pCVD442 sacB suicide vector derived from plasmid pUM24 Lee et al., 2012
pJN105 araC-PBAD cassette cloned in pBBR1MCS-5, Gmr Newman and Fuqua, 1999
pJN105::PA3800 pJN105 with wild-type copy of PA3800 gene under arabinose-inducible promoter This study
pJN105::PA5174 pJN105 with wild-type copy of PA5174 gene under arabinose-inducible promoter This study
Briefly, flanking sequences (∼600 bp) at both ends of each gene
were PCR amplified with primers listed in Table 2. Two inner
primers (upstream reverse primer and downstream forward
primer) are complementary to each other. In this strategy, the 3′-
end of the upstream sequence and the 5′-end of the downstream
sequence are annealed during PCR amplification without further
treatment. The deletion of the PA0420, PA3800, and PA5174
genes was confirmed by PCR and DNA sequencing.
Genetic Complementation of the 1PA3800
and 1PA5174 Mutants
To complement the 1PA3800 and 1PA5174, DNA fragments
containing the entire PA3800 and PA5174 genes were amplified
from the PAO1 genome and ligated into EcoRI/XbaI-treated
pJN105. The resultant plasmid and the control empty plasmid
(i.e., pJN105) were transferred into the 1PA3800 and 1PA5174
mutant by electroporation, respectively. Expression of PA3800 or
PA5174 gene is induced by 0.01% L-arabinose (Sigma).
Bacterial Growth in Airway Mucus
Secretion (AMS)
Bacterial cultures grown in LB for 8 h were diluted in PBS to
get bacterial suspensions with the 105 CFU/mL. Ten microliters
of each diluent was inoculated into 100 µL AMS to achieve the
initial inoculum size of ∼103 CFU in AMS. Bacterial cells were
then grown for 16 h in a humidified 37◦C incubator. Bacterial
growth was assessed by measuring the growth index. The values
for [CFU after 16 h in AMS / CFU after 0 h in AMS] were
calculated and plotted as the growth index.
Mouse Infection and Caenorhabditis
elegans Survival Test
Animal experiments were approved by the Committee on the
Ethics of Animal Experiments of Yonsei University College
of Medicine (IACUC permit number: 2013-0369-5). Animal
experiments were conducted following national guidelines
provided by the Korean government (Ministry for Food,
Agriculture, Forestry and Fisheries) and in strict accordance
with the institutional guidelines for animal care and use of
laboratory animals. To test the virulence of the 1bamB and
1fabY mutants in vivo, 8-week-old C57BL/6N inbred female
mice (Orient, Korea) were intranasally infected with 5 × 106
cells of each strain (n = 4). The lungs of the infected mice
were removed at 16 h post-infection. The harvested lungs were
homogenized, and the number of bacteria in each organ was
measured by quantifying CFUs. Caenorhabditis elegans survival
tests were performed as described previously (Go et al., 2014).
Electron Microscope
Lysozyme-treated bacterial cells were visualized using a scanning
electron microscope (SEM), as described previously (Yoon et al.,
2011). Briefly, fixed bacterial suspensions were stained with 1%
OsO4 (Sigma) and then coated with gold via an ion sputter (IB-
3 Eiko, Japan). SEM (FE SEM S-800, Hitachi, Japan) was used at
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TABLE 2 | Primers used in this study.
Gene name Direction Primer sequence (5′-3′)a Restriction enzymes
MUTANT CONSTRUCTION
PA0420 left Forward ACCTTGAGCTCGCCGAGAGATCGTCCAGGGT SacI
PA0420 left Reverse TCCGGGTGGAAGTCGCTGACAAGGCCCATGGGCTGTCTCC
PA0420 right Forward GGAGACAGCCCATGGGCCTTGTCAGCGACTTCCACCCGGA
PA0420 right Reverse TAGAGGAGCTCAGGGCCAGAGGCGGATGGAT SacI
PA3800 left Forward ACCTTGCATGCTGGTGGCAGCGCAACGGCAA SphI
PA3800 left Reverse ACGAGCTTGCCACCGTTGCCCACCATCTCAGGCCTCTCCC
PA3800 right Forward GGGAGAGGCCTGAGATGGTGGGCAACGGTGGCAAGCTCGT
PA3800 right Reverse TAGAGGCATGCGATCCCCAGGGCTTCCTGCA SphI
PA5174 left Forward ACCTTGAGCTCGTCCAGGCCGCCATCGAGTT SacI
PA5174 left Reverse GGCGCTCAGTCGAGCATGTCGCCTGCTGCGTTGTAGCCAC
PA5174 right Forward GTGGCTACAACGCAGCAGGCGACATGCTCGACTGAGCGCC
PA5174 right Reverse TAGAGGAGCTCCCGGTAGCGAGGAGTTCACC SacI
COMPLEMENTATION
PA3800 complementation (cloning to pJN105) Forward AATTCGAATTCAAGGAGATATACATATGGTGCAATGGAAACACGC EcoRI
Reverse ATATCTCTAGACTAGCGGATGGTGTAGGCGA XbaI
PA5174 complementation (cloning to pJN105) Forward AATTCGAATTCAAGGAGATATACATATGTCTCGACTACCGGTCATT EcoRI
Reverse ATATCTCTAGATCAGTCGAGCATGTCGCTGA XbaI
aRestriction enzyme recognition sequences are underlined.
an acceleration voltage of 20 kV. All images were processed using
ESCAN 4000 software (Bummi Universe Co., Ltd., Seoul, Korea).
Membrane Integrity Assays
Bacterial resistance against hypo-osmotic stress was measured by
monitoring the decrease of OD600 values. Each bacterial strain,
grown to mid-exponential phase was harvested and washed
with 1× PBS. The bacterial cells were resuspended in sterilized
deionized water. The OD600 of each bacterial suspension was
measured every 10 min for 60 min. The data were normalized
with their initial OD600-values. The PAO1, 1bamB, and 1fabY
mutants were also observed under confocal laser scanning
microscope (CLSM) with LIVE/DEAD R© BacLightTM Bacterial
Viability Kit to detect the difference in membrane integrity
among these bacterial strains.
Statistical Analysis
The experiments were repeated at least in triplicate, and data
are expressed as mean ± standard deviation (SD). Data were
analyzed using unpaired Student’s t-test, unless otherwise stated
and P < 0.05 were considered to be statistically significant. Log-
rank test was used to provide statistical significance in the C.
elegans lifespan experiments.
RESULTS
P. aeruginosa Is Highly Resistant to
Lysozyme
Prior literature demonstrated that P. aeruginosa can become
lysozyme-sensitive only when co-treated with EDTA at pH 8.0
(Voss, 1964) or pretreated with acetone or heat (Warren et al.,
1955). As expected, PAO1 grew unencumbered when grown in
LB media supplemented with 1 mg/mL lysozyme (Figure 1).
Likewise, two other Gram-negative species, Escherichia coli
(Ec) and Salmonella enterica serovar Typhimurium (St), also
grew normally in these conditions (Figure 1). These results
further support our notion that Gram-negative bacterial cells are
intrinsically resistant to lysozyme because their outer membrane
prevents lysozyme from accessing the peptidoglycan in the
periplasm. On the other hand, two Gram-positive species,
Bacillus subtilis (Bs) and Listeria monocytogenes (Lm), lost their
viability in response to the same treatment (Figure 1). Consistent
with previous reports (Bera et al., 2005, 2006), Staphylococcus
aureus (Sa) was completely resistant to the lysozyme treatment
(Figure 1). PAO1 growth was not affected, even in the presence
of 8 mg/mL lysozyme (data not shown), demonstrating an
exceptionally high resistance to lysozyme.
Dentification of Lysozyme-Sensitive PAO1
Mutants
In order to devise a better strategy for P. aeruginosa infection
control, it would be desirable to identify lysozyme-sensitive
mutants. We therefore constructed a Tn insertion mutant library
and screened it for mutants that had lost their resistance
to lysozyme treatment. Since lysozyme is more active in
environments with reduced ionic strength (Sorrentino et al.,
1982; Verhamme et al., 1988), bacterial growth was tested in
two-fold diluted LB media (termed 0.5× LB). Approximately
5,500 mutants were screened, three of which were determined
to lack lysozyme resistance. In each mutant, the transposon
insertion occurred in PA0420, PA3800, or PA5174 gene. To
further verify the effects of these gene disruptions, we generated
an in-frame deletion of each gene and examined cell growth in
the presence of lysozyme. In 0.5× LB, 1PA3800 and 1PA5174
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mutants exhibited significant growth inhibition in the presence
of 1.0 mg/mL lysozyme (Figure 2A). After 16 h of growth at
37◦C with lysozyme, the CFUs of these two mutants remained
similar to those at the time of inoculum (indicated by an arrow
on the y-axis), indicating that bacterial growth was prevented by
lysozyme at a physiological concentration. PA3800 gene encode
β-barrel assembly machinery protein B (BamB) involved in outer
membrane protein assembly (Jansen et al., 2012). PA5174 gene
encodes probable beta-ketoacyl synthase, which plays a role
in fatty acid biosynthesis (Yuan et al., 2012; Figure 2B). The
deletion of PA3800 gene did not result in any growth inhibition,
whereas the 1fabY mutant exhibited a slightly affected growth,
yielding ∼10-fold less viable cell counts after 16 h growth in 0.5
× LB media (Figure 2A). When these mutants were grown with
lysozyme, bacterial cells with crumbled rod-shaped morphology
were observed (Figure S1), further demonstrating that lysozyme,
an enzyme that degrades peptidoglycan polymers, damages the
bacterial cell wall structure.
PA0420, bioA gene, produces adenosylmethionine-8-amino-
7-oxononanoate aminotransferase, which is responsible for
biotin biosynthesis (Beaume et al., 2015). Of note, the 1bioA
mutant exhibited inactive growth, even in the absence of
lysozyme treatment, indicating that an interruption in biotin
FIGURE 2 | Identification of lysozyme-sensitive PAO1 mutants. (A)
Three PAO1 mutant strains were grown in the absence or presence of 1
mg/mL lysozyme in 0.5× LB. After 16 h growth, aliquots from each culture
were diluted and plated for CFU counting. Experimental conditions were
identical to those described in the legend of Figure 1. Bacterial cultures were
repeated in triplicate, and the mean ± SD values are displayed. *P < 0.05 vs.
CFU of untreated cultures. (B) Genetic information for the genes disrupted in
each mutant and the functions of the proteins they encoded.
synthesis leads to defective growth in P. aeruginosa. When the
mutant was grown in media supplemented with extraneous
biotin, its growth and lysozyme susceptibility were completely
restored (Figure S2). This result suggests that lysozyme sensitivity
of the 1bioA mutant is likely associated with its faulty growth;
therefore, we did not pursue any further investigation on this
particular mutant.
When wild type copy of bamB or fabY gene was expressed
by the arabinose-inducible promoter, each mutant became fully
resistant to lysozyme treatment (Figure 3). These results further
confirm that the lysozyme sensitivities observed in the mutants
are indeed caused by the deletion of bamB or fabY gene.
Lysozyme-Sensitive Mutants Are also
Susceptible to Treatment with Airway
Mucus Secretion
Airway mucus secretion (AMS) plays a role in the host
innate defense and contains various antimicrobial components
including lysozyme (Gi et al., 2015). To examine bacterial
response to AMS, we treated the bacterial strains with AMS
collected from primary cultures of three different human tracheal
tissues. In each treatment, 103 bacterial cells were inoculated
and incubated for 16 h. After the treatments, the number
of PAO1 cells increased to ∼5 × 106 cells (growth index of
FIGURE 3 | Restored lysozyme resistance of genetically
complemented mutants. The 1bamB and 1fabY mutants were
transformed with pJN105::bamB or pJN105::fabY plasmid, respectively. As a
control, each mutant was also transformed with the empty plasmid, pJN105.
Bacterial strains were grown in the presence of 1 mg/mL lysozyme for 16 h. To
induce the gene expression, 0.01% L-arabinose was also added in each
media. Aliquots of each culture were diluted and plated for CFU quantification.
Bacterial cultures were performed in triplicate, and the mean ± SD values are
displayed. *P < 0.05 vs. CFU of each mutant harboring pJN105.
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∼5,000), demonstrating the capability of wild type P. aeruginosa
to propagate in AMS (Figure 4). The growth of the 1bamB
mutant was not as robust as that of PAO1. The average growth
index of the mutant in AMS was ∼68 (Figure 4). Of note, the
growth of the1fabY mutant was more severely affected, yielding
the growth index of∼1.0. Together, these results suggest that two
lysozyme-sensitive mutants are less capable of proliferating in
AMS, a frontline substance that P. aeruginosa encounters during
the early stage of airway infection.
In vivo Infectivity of the
Lysozyme-Sensitive Mutants was
Ameliorated
We next examined whether these mutants were also defective
in establishing infections in vivo. To address this question,
we utilized two different animal infection models: mouse and
nematode. First, mice were intranasally infected with bacterial
cells. At 16 h post-infection, mouse lung homogenates were
prepared, and the bacterial cells were enumerated. Increased
numbers of PAO1 cells were recovered following the 16 h
infection (Figure 5A), demonstrating that wild type P. aeruginosa
can replicate inside the mouse airway. By comparison, decreased
numbers of 1bamB and 1fabY mutant cells were recovered,
indicating a compromise in their ability to multiply inside a host
airway (Figure 5A).
C. elegans is a nematode that has been widely used to study
host-microbe interactions (Go et al., 2014). Furthermore, C.
elegans is known to express 15 homologs of lysozyme that
act as digestive enzymes for bacterial prey and, therefore, as
key players for innate immunity (Mallo et al., 2002; Boehnisch
et al., 2011). Given these characteristics, we postulated that
FIGURE 4 | Bacterial growth in airway mucus secretion (AMS) prepared
from primary culture of human tracheal tissues. The wild type PAO1 and
its two mutants, 1bamB and 1fabY, were grown in three separate AMS
preparations for 16 h. Aliquots of each culture were diluted and plated for CFU
quantification. The values for CFU in16 h / CFU inoculum were calculated and
plotted as the growth index. Bacterial cultures were performed in triplicate,
and the mean ± SD values are displayed. *P < 0.05 vs. CFU of PAO1 cells.
C. elegans could serve as an appropriate model to study in vivo
infectivity of lysozyme-sensitivemutants. As shown in Figure 5B,
C. elegans lived significantly longer when fed 1bamB and, to
a greater extent, 1fabY mutants; the average lifespans were 9.2
± 0.5 (days) and 11.6 ± 0.6 (days), respectively. As expected, a
considerably shorter lifespan (6.6 ± 0.3 days) was observed in
worms grown by feeding on PAO1 cells (Figure 5B). Together,
these results demonstrate that lysozyme-sensitive mutants are
also less capable of establishing in vivo virulence.
Bacterial Cell Membrane Integrity was
Mildly and Severely Affected in 1bamB and
1fabY Mutants, Respectively
Because lysozyme targets bacterial peptidoglycan, we postulated
that the increased lysozyme sensitivity of the mutants may
be associated with altered bacterial cell membrane integrity.
To address this issue, we analyzed how the lysozyme-sensitive
mutants responded to hypo-osmotic stress. We also assessed
the penetration of propidium iodide, a fluorescent dye that
normally impermeable of healthy bacterial membrane, into
bacterial cells of each strain. When PBS-washed bacterial cells
were resuspended in distilled water, a marked and persistent
drop in OD600-values were observed in the 1fabY mutant over
1 h time period (Figure 6A). In contrast, bacterial cell density
monitored by measuring OD600-values was decreased only in the
later stage of the experiment for the case of the 1bamB mutant
(Figure 6A). Consistent with the hypo-osmotic resistance result,
1fabY mutant cells were more permeable to propidium iodide,
a red fluorescent dye that only stains bacterial nucleic acids
when the membrane integrity was compromised. Together, these
results demonstrate that bacterial membrane integrity is affected,
especially in the 1fabY mutant and such a defect likely accounts
for the enhanced sensitivity (i) to the AMS treatment (Figure 4)
and (ii) inside the C. elegans (Figure 5B).
1bamB Mutant Is Extremely Sensitive to
Antibiotics that Target Cell Wall Synthesis
We then explored whether lysozyme-sensitive mutants also
exhibited elevated sensitivity to antibiotic treatments. To
examine bacterial responsiveness to antibiotics of diverse
classes, we tested vancomycin (Day et al., 1993), ceftazidime
(O’Callaghan, 1986), ampicillin (Ghobashy and Chiori, 1984),
tobramycin (Hoff et al., 1974), and ciprofloxacin (Roy et al.,
1983), the first three of which target cell wall synthesis.
Tobramycin and ciprofloxacin inhibit protein synthesis andDNA
replication, respectively. At the concentrations tested, PAO1
was either unaffected or only mildly affected (Figures 7A–E).
Importantly, the 1bamB mutant completely lost its viability
in response to treatment with vancomycin, ceftazidime, and
ampicillin (Figures 7A–C). The viability of the 1fabY mutant
was also decreased about 100∼1,000 fold in response to the same
treatment (Figures 7A–C). The degree of growth inhibition in
these twomutants was not as great when treated with tobramycin
and ciprofloxacin (Figures 7D,E). Collectively, these results
suggest that (i) the 1bamB mutant is exceptionally sensitive to
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FIGURE 5 | Survival fitness and virulence of 1bamB and 1fabY mutants in vivo. (A) Bacterial counts recovered from the left lung lobes. The infection dose
was 5.0 × 106 cells per mouse (black arrow on the y-axis). Mice were infected with the indicated bacterial strains for 16 h. *P < 0.05 vs. CFU of PAO1 cells. (B)
Survival curves of the C. elegans N2 strain fed with PAO1 (blue), 1bamB (green), and 1fabY (black). *P < 0.05 vs. the survival rate of the PAO1-fed worms. In each
group, 20 worms were used. Statistical significance was determined by log-rank analysis.
FIGURE 6 | Bacterial membrane integrity tests of two lysozyme-sensitive mutants. (A) Bacterial cells resuspended in distilled water were monitored for their
changes in OD600 values at 10min intervals for 1 hr. Experiments were performed in triplicate, and the mean ± SD values are displayed. *P < 0.05 vs. OD600 of PAO1
at each time point. (B) Each bacterial culture was stained with Syto9 and propidium iodide and visualized by confocal laser scanning microscope (CLSM) as described
in Section Materials and Methods.
cell wall-targeting antibiotics and, therefore, (ii) BamBmay be an
effective target in the elimination of P. aeruginosa.
DISCUSSION
Recalcitrant P. aeruginosa infection remains a huge threat to
public healthcare. Increasing numbers of metallo-β-lactamase-
producing clinical isolates have been identified around the world
(Corvec et al., 2006; Chin et al., 2011; Jovcic et al., 2011; Piyakul
et al., 2012; Van der Bij et al., 2012), and strains exhibiting
resistance to colistin, a “last hope” antibiotic, have also been
isolated (Lee et al., 2014). Therefore, novel anti-Pseudomonas
strategies that do not generate escape mutants are required. We
postulate that one such approach is to exploit lysozyme, an anti-
bacterial innate immunoprotein that is abundantly present in the
human airway. In this study, we identified PAO1 mutants that
became sensitive to lysozyme treatment and provided the clinical
perspectives to control P. aeruginosa infections.
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FIGURE 7 | Antibiotic susceptibility of two lysozyme-sensitive PAO1 mutants. PAO1, 1bamB, and 1fabY mutants were treated in LB for 16 h with 100 µg/mL
Vancomycin (A), 0.5 µg/mL Ceftazidime (B), 25 µg/mL ampicillin (C), 0.2 µg/mL tobramycin (D), or 0.1 µg/mL ciprofloxacin (E). After a16-h incubation, aliquots from
each culture were diluted and plated for CFU enumeration. *P < 0.05 vs. CFU of untreated cultures. Antibiotic concentrations that do not affect PAO1 growth were
chosen for analysis.
The outer membrane of Gram-negative bacterial cells is a
physical barrier that prevents lysozyme from gaining access
to the peptidoglycan layer. EDTA-treated P. aeruginosa was
found to be sensitive to lysozyme; when grown with Mg2+, the
effect of EDTA-mediated increased susceptibility to lysozyme was
reversed (Witholt et al., 1976; Ayres et al., 1998). These results
suggest that outer membrane integrity is important for lysozyme
resistance. In this respect, it is not surprising that lysozyme-
sensitive mutants were also susceptible to antibiotics that target
peptidoglycan synthesis. Of particular interest, however, is the
extreme sensitivity of the 1bamB mutant against cell wall-
targeting antibiotics (Figure 7). Complete loss of viability was
observed in response to treatment with vancomycin, ceftazidime,
or ampicillin. These results demonstrate the potential of BamB
as a drug target, the inhibition of which could result in efficient
elimination of P. aeruginosa via a low dose of cell wall-targeting
antibiotics. The crystal structure of the BamB indicates that it
contains (i) a β-propeller fold with a central pore region and (ii)
protruding loops that mediate its association with BamA (Jansen
et al., 2012). BamA homologs in diverse bacterial species are
considered essential for viability (Voulhoux et al., 2003; Gentle
et al., 2004; Jansen et al., 2012). Given that BamB is an outer
membrane protein, we can seek to identify a potential inhibitor
that binds to the central pore region of BamB, thereby interfering
with its function. Alternatively, the association of BamB with
BamA could be targeted for inhibition. Mori and colleagues
showed that peptides homologous to a portion of BamA-binding
region of BamD can increase the efficacy of antibiotic-mediated
killing of P. aeruginosa (Mori et al., 2012). It will be important
to ask whether these peptides can also potentiate bactericidal
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action of lysozyme in vitro and inside the patient’s airway as
well.
The 1fabY mutant produced hypoacylated lipid A and
this change was proposed to be responsible for the increased
antibiotic sensitivity (Six et al., 2014). Our result in Figure 6
shows that the 1fabY mutant is more vulnerable to hypo-
osmotic stress than 1bamB. On the other hand, 1bamB mutant
cells are far more sensitive than 1fabY to cell wall-targeting
antibiotics (Figure 7). These findings suggest that alterations in
fatty acid synthesis or outer membrane protein assembly may
lead to unique cell surface changes, which result in distinct
consequences. Importantly, both1bamB and1fabY mutant are
equally susceptible to the treatment with 1.0 mg/ml lysozyme
(Figure 2).We therefore hypothesize that lysozyme can be widely
used in combination with any intervention that targets bacterial
cell surface either at the lipid or protein level. We anticipate that
the results provided here will stimulate future investigations.
Cerulenin, an anti-fungal agent, inhibits fatty acid
biosynthesis by inhibiting β-ketoacyl-acyl carrier protein
synthetase in E. coli (Buttke and Ingram, 1978). PAO1
FabY protein, however, exhibits low homology to the E.
coli counterpart. Our experiments demonstrated that cerulenin
at up to 200 µg/ml does not inhibit P. aeruginosa growth
(data not shown). To date, a wide range of fatty acid synthesis
inhibitors have been identified. These include isoniazid (Chan
and Vogel, 2010), triclosan (Wright and Reynolds, 2007), Irgasan
(Nishi et al., 2016), Kaempferol (Thors et al., 2008), Quercetin
(Zhao et al., 2014a), Apigenin (Brusselmans et al., 2005),
1,2,3,4,6-Penta-O-galloyl-β-D-glucose (Zhao et al., 2014b), and
Epigallocatechin gallage (Brusselmans et al., 2005). Although
many of these inhibitors are proved to be effective in eukaryotic
cells, these have not been actively tested in bacterial cells. It is
worthwhile to examine whether any of these inhibitors can exert
synergistic effects on inhibiting P. aeruginosa growth, when used
together with lysozyme.
In conclusion, this study uncovered a common aspect of two
different P. aeruginosamutants with pleiotropic phenotypes. Our
results show that interventions that affect fatty acid synthesis or
outer membrane protein assembly may facilitate the eradication
of P. aeruginosa with the aid of physiological concentration of
lysozyme. Insights gleaned from this study will be useful in
devising new strategies to combat one of the most resistant
infections.
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